&nbsp;丝裂原活化蛋白激酶激酶1在胃癌中的表达及其临床意义

赵媛; 陶月佳; 余广福; 郭嘉欣; 李梦琪; 徐远义; 黄允宁

doi:10.16098/j.issn.0529-1356.2022.03.006

PDF(7742 KB)

解剖学报 ›› 2022, Vol. 53 ›› Issue (3) : 309-316. DOI: 10.16098/j.issn.0529-1356.2022.03.006

肿瘤生物学

丝裂原活化蛋白激酶激酶1在胃癌中的表达及其临床意义

赵媛¹陶月佳¹ 余广福² 郭嘉欣¹ 李梦琪¹ 徐远义^1* 黄允宁^2*

作者信息 +

Expression of mitogen-activated protein kinase kinase 1 in gastric cancer and its clinical significance

ZHAO Yuan¹ TAO Yue-jia¹ YU Guang-fu² GUO Jia-xin¹ LI Meng-qi¹ XU Yuan-yi^1* HUANG Yun-ning^2*#br#

Author information +

文章历史 +

摘要

目的探讨丝裂原活化蛋白激酶激酶1（MAP2K1）在胃癌中的表达及其临床意义。方法免疫组织化学及Western blotting检测MAP2K1在胃癌组织和细胞中蛋白水平的表达；免疫荧光染色观察细胞形态及MAP2K1的表达位置；StarBase及Oncomine 数据库对MAP2K1进行数据挖掘，分析MAP2K1 mRNA在胃癌组织中的表达情况；UALCAN数据库分析MAP2K1 mRNA的表达与临床病理特征的相关性；Kaplan Meier-Plotter 在线分析工具进行生存分析; GEPIA2数据库挖掘MAP2K1与胃癌干细胞相关因子和耐药相关因子的关系。结果免疫组织化学、免疫荧光和Western blotting结果表明，在胃癌组织和细胞中MAP2K1蛋白为高表达，且MAP2K1表达在胃癌细胞质中。由多种数据库分析得出，MAP2K1 mRNA在胃癌组织的表达量高于正常胃组织，其表达量与胃癌分期、分级、淋巴结转移和患者性别密切相关，MAP2K1高表达组的胃癌患者总体生存率明显低于低表达组,其原因可能与胃癌干细胞特性和耐药性相关。结论 MAP2K1在胃癌中高表达，其表达水平可能通过调控干细胞相关因子与耐药相关因子影响患者不良预后。MAP2K1或可成为判断胃癌患者预后的新型诊断标志物。

Abstract

Objective To investigate the expression of mitogen-activated protein kinase kinase 1 (MAP2K1) in gastric cancer and its clinical significance. Methods Immunohistochemistry and Western blotting were used to detect the protein expression of MAP2K1 in gastric cancertissues and cells. The morphology and the expression position of MAP2K1 were observed by immunofluorescence. MAP2K1 mRNA expression in gastric cancer tissues was analyzed by data mining of Starbase database and Oncomine database. The correlation between MAP2K1 mRNA expression and clinicopathological features was analyzed by UALCAN database. Survival analysis was performed using Kaplan Meier-Plotter online analysis tools. GEPIA2 database mining the relationship between MAP2K1 and gastric cancer stem cell related factors and drug resistance related factors. Results Immunohistochemistry, immunofluorescence and Western blotting showed that MAP2K1 protein was highly expressed in gastric cancer tissues and cells, and MAP2K1 was expressed in the cytoplasm of gastric cancer. According to the analysis of various databases, the expression of MAP2K1 mRNA in gastric cancer tissue was higher than that in normal gastric tissue, and the expression of MAP2K1 mRNA was closely related to gastric cancer stage, grade, lymph node metastasis and patient gender, and the overall survival rate of gastric cancer patients in the group with high MAP2K1 mRNA expression was significantly lower than that in the group with low MAP2K1 mRNA expression, which may be related to the characteristics of gastric cancer stem cells and drug resistance. Conclusion MAP2K1 is highly expressed in gastric cancer, and its expression level may affect the poor prognosis of patients by regulating stem cell related factors and drug resistance related factors. MAP2K1 may be a new diagnostic marker to determine the prognosis of gastric cancer patients.

导出引用

赵媛陶月佳余广福郭嘉欣李梦琪徐远义黄允宁. 丝裂原活化蛋白激酶激酶1在胃癌中的表达及其临床意义[J]. 解剖学报. 2022, 53(3): 309-316 https://doi.org/10.16098/j.issn.0529-1356.2022.03.006

ZHAO Yuan TAO Yue-jia YU Guang-fu GUO Jia-xin LI Meng-qi XU Yuan-yi HUANG Yun-ning. Expression of mitogen-activated protein kinase kinase 1 in gastric cancer and its clinical significance[J]. Acta Anatomica Sinica. 2022, 53(3): 309-316 https://doi.org/10.16098/j.issn.0529-1356.2022.03.006

中图分类号： R735.2

参考文献

［1］Zhou T, Chen S, Mao X. miR-145-5p affects the differentiation of gastric cancer by targeting KLF5 directly［J］. J Cell Physiol, 2019, 234(5): 7634-7644.

［2］Liu DT, Yang ZhJ, Ding B, et al. Effects of microRNA-4286 on the growth,vmigration and invasion of gastric cancer cell line HGC-27 by regulating inositol polyphosphate-4-phosphatase typeⅠ［J］. Acta Anatomica Sinica, 2021, 52(3): 405-409.(in Chinese)

刘东涛, 杨志娟, 丁波, 等. 微小RNA-4286调控肌醇多聚磷酸-4-磷酸酶Ⅰ型对胃癌细胞系HGC-27生长、迁移及侵袭的影响［J］. 解剖学报, 2021,52(3): 405-409.

［3］Huang Y, Zou Y, Lin L, et al. miR-101 regulates the cell proliferation and apoptosis in diffuse large B-cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway［J］. Oncol Rep, 2019, 41(1): 377-386.

［4］Chuang J, Wang C, Guo Y, et al. MAP2K1 mutations in advanced colorectal cancer predict poor response to anti-EGFR therapy and to vertical targeting of MAPK pathway［J］ .Clin Colorectal Cancer, 2021, 20(1): 72-78.

［5］Cedric BC, Souraka TDM, Feng YL, et al. CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1［J］. Eur Rev Med Pharmacol Sci, 2020, 24(19): 9924-9931.

［6］You J, Zhang Y, Li Y, et al. MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer［J］. Am J Cancer Res, 2015, 5(9): 2730-2744.

［7］Cheaney B, Bowden S, Krause K, et al. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion［J］. Acta Neuropathol Commun, 2019, 7(1): 110.

［8］Wang X, Cheng G, Miao Y, et al. Piezo type mechanosensitive ion channel component 1 facilitates gastric cancer omentum metastasis［J］. J Cell Mol Med, 2021, 25(4): 2238-2253.

［9］Tan Z. Recent advances in the surgical treatment of advanced gastric cancer: a review［J］. Med Sci Monit, 2019, 25(25): 3537-3541.

［10］Liang X, Zhu J, Li Y, et al. Treatment strategies for metastatic gastric cancer: chemotherapy, palliative surgery or radiotherapy［J］? Future Oncol, 2020, 16(5): 91-102.

［11］Zhao Q, Cao L, Guan L, et al. Immunotherapy for gastric cancer: dilemmas and prospect［J］. Brief Funct Genomics, 2019, 18(2): 107-112.

［12］Jain AP, Patel K, Pinto S, et al. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma［J］. Sci Rep, 2019, 9(1): 18793.

［13］Schmidt J, RamisZaldivar JE, Nadeu F, et al. MAP2K1Mutations of are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation［J］. Blood, 2017, 130(3): 323-327.

［14］Chuang J, Wang C, Guo Y, et al. MAP2K1 mutations in advanced colorectal cancer predict poor response to anti-EGFR therapy and to vertical targeting of MAPK pathway［J］. Clin Colorectal Cancer, 2021, 20(1): 72-78.

［15］Cui X, Zhang A, Liu J, et al. Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression［J］. Biochem Biophys Res Commun, 2018, 504(4): 784-791.

［16］Pénzváltó Z, Lánczky A, Lénárt J, et al. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer［J］. BMC Cancer, 2014, 14(1): 837.

［17］Pérez G, López-Moncada F, Indo S, et al. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells［J］. Oncol Rep, 2021, 45(5): 58.

［18］Dai JZ, Jin HF. Research progress of stem cell markers for gastric cancer［J］. Chinese Journal of Gerontology, 2020, 40(24): 5364-5371. (in Chinese)

代俊泽, 金海峰. 胃癌干细胞标志物的研究进展［J］. 中国老年学杂志, 2020, 40 (24): 5364-5371.

［19］Zhao JJ, Zhao XQ. Function of X-linked suppressor protein and its role in tumor［J］. Chinese Journal of Biochemistry and Molecular Biology, 2021, 37(3): 321-327. (in Chinese)

赵俊杰, 赵晓琴. X连锁抑制蛋白的功能及其在肿瘤中的作用［J］. 中国生物化学与分子生物学报, 2021, 37(3): 321-327.

［20］Li YB, Lin LZh, Wang Ch, et al. Effects of Yiqi Chutan Formula combined cisplatin on xenografts inhibition and expressions of Bax,Bcl-2 in platinumresistant lung cancer［J］. Chinese Journal of Traditional Chinese Medicine, 2019, 34(2): 755-758. (in Chinese)

李元滨, 林丽珠, 王超, 等. 益气除痰方联合顺铂对可以治愈的皮下移植瘤生长及Bax, Bcl-2表达的影响［J］. 中华中医药杂志, 2019,34(2): 755-758.

［21］Chen XY, Yang Y, Wang JQ, et al. Overexpression of ABCC1 confers drug resistance to betulin ［J］. Front Oncol, 2021, 11(11): 640656.

［22］Kubiliute R, Januskeviciene I, Urbanaviciute R, et al. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line ［J］. Sci Rep, 2021, 11(1): 6556.